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** ABSTRACT: 
 
     Parkinson’s disease (PD) represents in today’s society one of the most common 
neurodegenerative diseases. An important progress has been made in recent years, in the 
development of therapeutic treatments for this disease. However, no cure has been found yet. 
When discovered, the treatment of PD by the use of L-dopa as a therapy was anticipated to be 
a sufficient one. But with time, a loss of effectiveness has been noticed in patients after five 
to fifteen years of this treatment. Therefore we searched for a way of treating Parkinson’s 
disease that would give rise to no or few side effects to the patients, so we decided to research 
stem cell therapy. This paper contains studies of the function of a normal brain in order to 
then have a better insight on the processes occurring in the brain of the patients suffering 
from PD. For this, we used scientific journals, reviews and books. We also looked into 
theoretical knowledge of stem cells, the different types of stem cells that exist and how each 
of them could be used to treat Parkinson’s disease. Based on the information from various 
research articles, we made the following conclusions: embryonic stem cells (ESCs) and 
somatic cells induced into pluripotent stem cells are the most efficient. However, ESCs have 
a high risk of tumor formation and rejection of the graft from the host organism. While using 
induced pluripotent stem (iPS) cells, there is an extremely low risk of graft rejection since the 
cells are taken from the patient; nonetheless, the risk of tumor formation remains present.  
1st Semester, Fall 2009: Juliette Tavenier, Evelina Martinenaite, Elayne Elvira Lorenzen & Ursula Izabel Waltemath 
3 
 
** ACKNOWLEDGEMENTS: 
 
     Our group would like to express their sincere gratitude to Jette Rank for her continuous 
support, advices and assistance as our supervisor. Her very discerning comments and critics 
guided us throughout the development of our project. 
     We would also like to give thanks to the professor Elisabeth Bock (København 
Universitet) for inspiring us to work on Parkinson’s disease instead of Alzheimer’s disease. 
Our group would now like to express their gratefulness to Elisabet Andersson and Thomas 
Perlmann from Karolinska Institutet of Stockholm (Sweden) for their willingness to meet us 
in their laboratories and to answer our questions even though we weren’t able to attend the 
meeting.  We really appreciated the kindness of Pia Jensen, PhD student from SydDansk 
University of Odense (Denmark). Her help in answering most of our questions and in 
providing us congruent information was very relevant for our report.  
     Our group is very thankful to our opponent group and supervisors for their discriminating 
critics and comments. To finish, we’re grateful to all the persons for their direct or indirect 
involvement during the realization of our project.  
  
1st Semester, Fall 2009: Juliette Tavenier, Evelina Martinenaite, Elayne Elvira Lorenzen & Ursula Izabel Waltemath 
4 
 
TABLE OF CONTENTS: 
 
** AIM OF THE PROJECT                                                 6 
** RELEVANCE TO THE SEMESTER THEME                    6 
 
1. INTRODUCTION                                                                                                         7 
 
2. PROBLEM  FORMULATION                                             8 
 
3. PROBLEM ANALYSIS                                                                                                8 
 
4. METHOD                                                                                9 
 
5. RESULTS                                                                                                                     10 
 
5.1 BACKGROUND KNOWLEDGE FOR PARKINSON’S DISEASE….………………..10 
 Gross anatomy of the brain…………………………………………………………..10 
 Basal ganglia……………………….………………………………………………...12 
 Basic knowledge about the function of the brain………………………….………...16 
 Dopamine and its metabolism in neurons of normal brain..........................................21 
 Historical background of Parkinson’s disease……………..………………………...22 
 Causes of Parkinson’s disease……………………………………………………….23 
 Imaging of Parkinson’s disease……………………………………….……………..24 
 Treatment of Parkinson’s disease…………...……………………………………….25 
 Fetus’ development.………….………………………………………………………27 
 
 
5.2 DISCOVERY ON HUMAN STEM CELLS.………………………….………………...28 
 
1st Semester, Fall 2009: Juliette Tavenier, Evelina Martinenaite, Elayne Elvira Lorenzen & Ursula Izabel Waltemath 
5 
 
 
 
5.3 STEM CELL……...……………………………………………………………………...29 
 Definition and potential………….…………………………………………………..29 
 Stem cell division…………………………………………………………………….31 
 Sources of stem cells……………………………………………..…………………..32 
 Embryonic mesencephalon tissue………………………………………………...….33 
 Neural stem cells………………………………………………………………….….34 
 Human embryonic stem cells…………………………………………………….…..34 
 Embryonic stem-like induced pluripotent stem cells……...……………….………...36 
 Human umbilical cord blood stem cells…………………………….……………….37 
 
 
5.4 STEM CELL THERAPY FOR PARKINSON’S DISEASE…………………...………..38 
 Stem cells from the fetal ventral mesencephalon…………………………...…...38 
 Embryonic stem cells, neural stem cells and induced pluripotent stem cells...…40 
 Transplantation……  ……………………………………….…………………...43 
 Immune response...…………………………………...………………………….44 
 Risk of tumor formation………………………………...……………………….44 
 
5.5 ETHICAL ASPECTS…………………………...………………………………………..45 
 
 
6. DISCUSSION                                                                                                              46 
 
7. PERSPECTIVES                                                                                                         47 
 
8. REFERENCES                                                                                                            49 
 
 
APPENDIX                                                                                                                        54 
 
ABBREVIATIONS                                                                                                            57 
1st Semester, Fall 2009: Juliette Tavenier, Evelina Martinenaite, Elayne Elvira Lorenzen & Ursula Izabel Waltemath 
6 
 
** AIM OF THE PROJECT: 
     The main aim of the project is to analyze stem cell therapy as a means to treat Parkinson’s 
disease. In this report, we explore the different types of stem cells and the way in which each 
of them can be used as therapeutics. With these examinations, we wish to be able to suggest 
the most suitable type of stem cells that could be employed to improve the lives of the ones 
suffering from Parkinson’s disease. 
     Studying this neurodegenerative disease also represents for our group, a way of 
succeeding to satisfy even if not totally, our thirst for knowledge in Biology and more 
accurately, our desire of enriching our understanding on Neuroscience. 
 
 
 
 
 
** RELEVANCE TO THE SEMESTER THEME: 
Semester theme: Application of natural sciences in technology and society. 
 
          Nowadays, Parkinson’s disease represents an important problem in society. Many 
people are affected by this disease. Being affected causes much suffering for the patient as 
well as the family, who has to endure the pain caused by their powerlessness to relieve the 
suffering of their loved one. Technology plays an immense role in the striving to cure this 
disease.  Indeed, technological advancements offer new opportunities and the chance for 
better research in hopes of more cures, resulting in a healthier and more balanced society. A 
lot of energy is spent by researchers on assessing stem cell therapy as a novel therapeutic 
treatment for neurodegenerative disorders like PD (Isacson, 2004).  
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1.  Introduction 
 
     According to statistics, each year millions of people are diagnosed with Parkinson’s 
disease. This life-threatening disease has no social, economic, ethnic or geographic 
boundaries and affects both men and women equally. Although the condition usually 
develops after the age of 65, about 15% are diagnosed under 50. Average life expectancy 
after diagnosis of Parkinson’s disease is 15 years (Lees et al, 2009). 
     Parkinson’s disease is the second most common neurodegenerative disorder and affects 
almost 1% of the population above 50 years of age (Paul G et al,. 2006) This disease was first 
described in 1817. Typical symptoms of Parkinson’s disease include tremor, slowness of 
movement, stiffness and difficulty with balance. Other signs may include small cramped 
handwriting, muffled speech, shuffling walk, stiff facial expression and depression. The 
symptoms of Parkinson’s disease normally occur when about 80% of the dopamine 
producing cells are damaged (Pavese and Brooks, 2009). This disease is a big problem for the 
society, because people with Parkinson’s disease cannot have a normal way of life and 
require long term medical treatment which is very expensive. Unfortunately there is no 
specific cure for Parkinson’s disease, but there are several effective medicines that help ease 
the symptoms. Thus, the possibility to use stem cell therapy to regenerate damaged brain 
regions might be a new effective treatment.  
     Several tests support the use of stem cells for treating Parkinson’s. The mission is to find 
the most precise method which will give the best results while satisfying ethical principles. In 
attempting to do so, we have several sources of stem cells, some with more potential than 
others. These stem cells and their sources are : Fetal tissue from the ventral mesencephalon 
(VM tissue), neural stem cells (NSCs) from embryonic/fetal or adult brain, embryonic stem 
cells (ESCs) obtained from the inner cell mass of the blastocyst, ES-like induced pluripotent 
stem (iPS) cells along with other stem cells, such as umbilical cord, placenta and bone 
marrow stem cells. 
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2.  Problem formulation: 
 
Which kind of stem cells would be the most suitable to use in the treatment of 
Parkinson’s disease? 
 
Sub questions:  
- How are the stem cells transferred to specific regions of the brain?  
- How are neurons generated from stem cells?  
- What are the ethical issues surrounding the sources and the use of stem cells? 
- Is there a possibility of developing tumors with this form of treatment?  
 
 
 
 
3.  Problem analysis: 
 
“The most suitable”  
     To determine which of the different type of stem cells would be the most suitable to treat 
Parkinson’s disease, various characteristics should be taken into consideration. First of all, 
the kind of stem cells chosen should be the one giving rise to the fewest number of side 
effects. Then, the improvement - meaning the disappearance or restriction of the parkinsonian 
symptoms, should last as long as possible. To finish, chosen stem cells should satisfying 
ethical principles the most.  
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4.  Method 
 
          In order to obtain the information needed for the realization of our project, we 
researched literature on the function of a normal brain and the function of a brain from a 
person suffering from Parkinson’s disease, before analyzing what stem cells are and how they 
could be used as a treatment for this degenerative disease. Therefore, we studied scientific 
reports, journals, reviews and books.  
 
     We got in contact with the professor Elisabeth Bock (København Universitet), then the 
PhD student and professor Elisabeth Andersson and Thomas Perlmann from Karolinska 
Institutet of Stockholm (Sweden) who gave us relevant advice.  Our group also contacted the 
PhD student Pia Jensen from University of Southern Denmark in Odense, who has a broad 
knowledge in the treatment of PD with stem cells. She helped us by answering our questions 
and providing us with sufficient literature. 
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4.  Results 
   4.1 Background knowledge for Parkinson's disease 
 Gross anatomy of the brain: 
 
     The nervous system is the body’s means of communication and decision-making. The 
peripheral nervous system (PNS) is made up of nerves. Then, the central nervous system 
(CNS) is made up of the spinal cord and the brain. The brain is split into three main parts: the 
cerebrum, the cerebellum and the brain stem (Serendip, 2009) 
     The brain is subdivided into the cerebrum, brainstem and cerebellum (see figure 1). Each 
of these subdivisions of the brain comprises antecedents (see the table below) (Noback et al., 
2005).  
 
Table 1: Subdivisions of the Brain and their antecedents 
Cerebrum 
- telencephalon 
- diencephalon 
Brainstem 
- mesencephalon (midbrain) 
- metencephalon (pons) 
- myelemcephalon (medulla oblongata) 
Cerebellum - metencephalon 
 
 
 
 
 
Figure 1: Subdivisions of the brain: cerebrum, brainstem and cerebellum. (The internet encyclopedia of science: “ 
midbrain”) 
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• Cerebrum: The cerebrum, which is often referred to as the cortex, is the largest part of 
the brain. This part is responsible for higher brain functions such as action and 
thought. The cortex can be divided into four sections which are called “lobes”: the 
frontal lobe, parietal lobe, occipital lobe and temporal lobe (refer to figure 1). The 
cerebral cortex is very wrinkled which increases the surface area of the brain and the 
amount of neurons inside it, in turn making the brain more efficient (Serendip, 2009). 
The cerebrum divides into two halves which are called the right and left hemispheres. 
Although these two hemispheres look symmetrical, they are known to function 
differently.  
 
 
Figure 2: The four sections of the cortex.: the frontal lobe which is responsible for reasoning, parts of speech, planning, 
emotions, movement and problem solving. The parietal lobe is associated with orientation, movement, recognition and 
perception of stimuli. The Occipital lobe is responsible for visual processing. The temporal lobe is associated with memory, 
speech, and with perception and recognition of auditory stimuli (Enchanted learning, 2009), (Serendip, 2009). 
 
 
• Cerebellum: The cerebellum, sometimes referred to as “little brain”, is associated with 
coordination and regulation of movement, balance and posture. (Serendip, 2009) 
Similar to the cerebrum, the cerebellum also has two hemispheres and a very folded 
surface (Enchanted learning, 2009). 
 
• Brain Stem: The brain stem, known to be the “simplest part of the brain”, is 
associated with basic vital life functions (Serendip, 2009). This structure is 
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responsible for heartbeat, blood pressure, and breathing along with the responsibility 
for the motor sensory pathways to the face and body (Enchanted learning, 2009). The 
midbrain (mesencephalon) is part of the brain stem.  
 
 Basal ganglia 
 
     Since Parkinson’s disease is characterized by dopamine deficiency, it is relevant to 
describe processes in regulation of which dopamine is important. In the brain dopamine 
modulates movement control in the basal ganglia (Best et al, 2009). Basal ganglia (BG) 
consists of five subcortical nuclei: putamen and nucleus caudate (collectively called 
striatum), globus pallidus which consists of the pars interna and the pars externa parts, 
nucleus subthalamicus and substantia nigra which is composed of the pars compacta and the 
pars reticulata parts (see figure 3). BG is known to be important in voluntary motion 
initiation, emotional and cognitive functions (Bartels and Leenders, 2009). 
 
 
 
Figure 3: Placement of the basal ganglia in the brain.  
(The basal ganglia. 
http://biomed.brown.edu/Courses/BI108/BI108_2003_Groups/Deep_Brain_Stimulation/basalganglia.html (on the web 
01.12.09) 
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     The basal ganglia comprises a complex network of parallel loops which integrate cerebral 
cortical regions, basal ganglia nuclei and thalamus. Motor circuits in this complex are 
projected to striatum, especially to putamen. Substantia nigra pars compacta (SNc) balances 
direct and indirect pathways of movement control in basal ganglia (BG). In the direct 
pathway SNc excites neurons of the striatum by affecting D1 dopamine receptors on their 
membrane (Jensen, 2006). From striatum signals are projected to globus pallidus pars interna 
(GPi) and substantia nigra reticulata (SNr) (see figure 4). SNr and GPi are known as the 
output nuclei of basal ganglia and project their signals to thalamus. In direct pathway GPi and 
SNr are inhibited and their inhibitory effect on thalamus is reduced, which leads to 
facilitation of movements (Bartels and Leenders, 2009).  
 
  
Figure 4: Direct and indirect circuits in basal ganglia.  
 
SNc 
Inhibition     
(D2 receptors) 
GPi/SNr 
Thalamus 
STN 
Excitation 
Inhibition 
Movement 
inhibition 
Striatum 
Inhibition 
GPe 
Inhibition 
Indirect pathway 
SNc 
Striatum 
GPi/SNr 
Thalamus 
Excitation    
(D1 receptors) 
Inhibition 
Disinhibition 
Movement 
facilitation 
Direct pathway 
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     Indirect pathway connects striatum with globus pallidus pars externa (GPe) and 
subthalamic nucleus (STN). In this pathway SNc inhibits striatum through D2 dopamine 
receptors (Jensen, 2006). Indirect pathway stimulation leads to inhibition of GPe and STN 
and excitation of GPi and SNr (see figure 4). This results in increase of their inhibitory effect 
on thalamus and leads to movement suppression (Bartels and Leenders, 2009). 
     Based on this classical model of direct and indirect circuits in BG, it is thought that 
movement control function of basal ganglia is the result of opposing effects of inhibitory 
effect of direct pathway and excitatory effect of indirect pathway (Bartels and Leenders, 
2009).. Since dopamine released by SNc affects striatal neurons in two ways by exciting D1 
(direct pathway) and inhibiting D2 receptors (indirect pathway), SNc plays a crucial role in 
circuit control in BG.  
     According to the same model of movement control in basal ganglia in a normal brain, 
dopamine deficiency results in reduced excitation and increased inhibition of direct and 
indirect pathway respectively, which then causes excessive activation of outputs of GPi and 
SNr and increased inhibition of thalamocortical and brainstem motor systems. This in turn 
results in parkinsonian motor features (Jensen, 2006).  
     However classical model of functioning of basal ganglia described above is not suitable to 
show how specific motor abnormalities emerge in Parkinson’s disease, but supposedly motor 
and non-motor features are the result of interaction between basal ganglia and other regions 
of the brain.  
     It is known that circuits inside basal ganglia mainly serve as feedback-stabilization for 
specific motor regions in the cortex. Decrease in dopamine concentration leads to 
destabilization of this network which then results in synchronization of activity of several 
loops in basal ganglia. Normal characteristic of basal ganglia is the uncorrelated activity of its 
subcircuits. Circuit synchronization in GPi after nigrostrial dopamine depletion (as in 
Parkinson’s disease) may lead to motor defects. Other symptoms of PD might be explained 
by the fact that beside motor circuit, basal ganglia is also connected to:  
− oculomotor circuit – involved in saccadic(sporadic) eye movements control; 
− dorsolateral circuit – thought to be involved in memory and orientation in space; 
− orbitofrontal circuit – thought to be involved in behavior control.   
Signals of these circuits are projected through caudate nucleus. Therefore, symptoms of 
Parkinson’s disease can be the result of deficiency in specific regions in striatum and specific 
cortical pathway to which it is connected (Bartels and Leenders, 2009). 
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     Dopaminergic neurons are located mainly in substantia nigra (SN) (mostly in SNc), but 
SN forms connections to all areas of BG (Jensen, 2006). The highest concentrations of 
dopamine can be observed in putamen and caudate nucleus (see figure 5). As mentioned 
before, putamen and caudate nucleus together are referred to as striatum and are the main 
areas of signal projection from SN. Therefore loss of dopaminergic neurons in SN mostly 
affects striatum, which can be seen in the decrease in concentration of dopamine in PD 
compared to its level in the normal brain (see figure 5).  
 
 
Figure 5. Concentrations of dopamine in control (normal) and Parkinson’s disease brain.  Thala, anterior thalamus; Thalvl, 
ventral lateral thalamus; Thalva, ventral anterior thalamus; Thalm, medial thalamus; Thalcm, centromedial thalamus; STN, 
subthalamic nucleus; GPL, lateral globus pallidus; GPM, medial globus pallidus; Nacc, nucleus accumbens; Put, anterior 
putamen; CNcau, tail of caudate nucleus; CNcorp, body of the caudate nucleus; CNcap, head of caudate nucleus; SNr, substantia 
nigra pars reticulata; SNc, substantia nigra pars compacta; Gpre, precentral gyrus; Gpost, postcentral gyrus; fr Ctx, frontal 
cortex. (Siegel GJ et al, 1999) 
 
     As described above, hallmark of Parkinson’s disease is depletion in concentration of 
dopamine. However, symptoms of PD may also be the result of degeneration of neuronal 
systems other than dopaminergic (eg. noradrenergic, serotonergic or cholinergic) (Bartels and 
Leenders, 2009).  
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 Basic knowledge about the function of the brain:  
 
     The brain is composed of fundamental units or building blocks, the nerve cells (neurons) 
and of supporting cells, neuroglia (glia). The nerve cells provide an immense number of lines 
of communication in the nervous system that can then carry out the different aspects of the 
behavior and control directly or indirectly the whole body (Nicholls et al., 2000). To process 
information, the brain uses two types of electrical stereotyped signals: localized graded 
potential (spread over short distances) and action potentials (conducted rapidly over long 
distances). To transmit information processed to target cells, neurons release chemical 
transmitter molecules at specialized junctions called synapses. The shape and position of a 
neuron, the origin and destination of its signals in the neural network provide information to 
its function (Nicholls et al., 2000).  
 
     Neurons are composed of a cell body (including a nucleus and organelles) (see figure 6). 
From the cell body arise short branches (dendrites) on which other neurons can form 
synapses (sites for cell-to-cell communication) and that can conduct impulses; and a long 
extension called axon which transfers the signal to the other neurons by forming a connection 
with them (Nicholls et al., 2000). Axon (see figure 6), the part of a neuron specialized for 
transmission of coded information arises from the axon hillock of the cell bodies. Then each 
axon extends for a very small distance before arborising (branch out like trees) into terminal 
branches (Noback et al., 2005). Each of those branches ends as a synapse (site of contact of 
one neuron with another) with the cell body, dendrite or axon of another nerve cell. 
     The synaptic cleft, a submicroscopic space, is present between the end of one neuron and 
the cell body, dendrite or axon of another neuron (Noback et al., 2005).  
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Figure 6: The structure of a neuron, its cell body and its processes (dendrites and axon), (Campbell and Reece, 2005) 
 
      
     Neuroglia (glia) represents the supportive cells that surround the cell bodies, dendrites and 
axons of nerve cells (Noback et al., 2005). They are 10-50 times more numerous than neurons 
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depending on the region of the central nervous system (CNS: brain and spinal cords) and 
therefore, glia constitute one-half of the total volume of the human brain. One of the essential 
roles of glia cells is to maintain and sustain neurons and their circuits, and to release trophic 
factors (factors that promote cellular growth, differentiation, and survival).  
 
     Glial cells in the central nervous system (CNS) can be classified into four types: 
- astrocytes (astroglia) 
- oligodendrocytes (oligodendroglia) 
- microglia 
- ependymal cells 
 
     Oligendendroglial cells grow around axon, forming many layers of myelin sheaths (see 
figure 6) and providing electrical insulation (Campbell and Reece, 2005). In embryos, some 
supporting cells have the function of forming tracks along which newly produced neurons 
travel from the neural tube. These cells are called radial glia. Those cells and astrocytes have 
both the possibility to act as stem cell by giving rise to neurons and other supporting cells. 
“Researchers view these multipotent precursors as a potential way to replace neurons and glia 
that are lost to injury or disease.” (Campbell and Reece, 2005) 
 
     The information processing is decomposed in three steps: sensory input, integration and 
motor output. The sensory input is handled by sensory neurons transmitting information from 
sensors that detect external stimuli (e.g. light, sound) and internal conditions (e.g. blood 
pressure) to the CNS (Campbell and Reece, 2005). There, the sensory input is integrated 
(analyzed and interpreted) by interneurons. Motor output leaves the CNS via motor neurons, 
which then communicate with effector cells (muscle cells or endocrine cells).  
     Action potentials, one of the electrical stereotyped signals used to process information is 
the signal conducted by axons (Campbell and Reece, 2005). They represent a rapid change in 
the membrane potential of an excitable cell in response to a stimulus. After action potentials 
have been produced and conducted to the terminal of an axon, they generally stop there. 
Action potentials are not transmitted to other cells but the information is, through in most of 
the cases, chemical synapses. The presynaptic neuron (transmitting cell; see figure 6) 
synthesizes the neurotransmitter and packages it in synaptic vesicles. Once released, the 
neurotransmitter diffuses across the synaptic cleft, gap between the presynaptic neuron and 
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the postsynaptic cell (receiving cell), before binding to a receptor (Campbell and Reece, 
2005). The information is then transferred to the opposite synaptic terminal and therefore, to 
the postsynaptic cell. 
 
     Neurotransmitters are chemical messengers that are released through the presynaptic 
membrane into the synaptic cleft. They are used to pass a signal to a receiving neuron by 
binding to its receptors on the postsynaptic membrane. Each neurotransmitter binds to a 
specific group of receptors (Campbell and Reece, 2005). Table 2 below shows major types of 
neurotransmitters, their structure and functions.  
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2: The major known neurotransmitters 
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 Dopamine and its metabolism in neurons of normal brain 
 
     Since Parkinson’s disease is characterized by the loss of dopamine producing neurons, it is 
important to focus on the structure and metabolism of this neurotransmitter in neurons of a 
healthy brain.  
     Dopamine (Figure 7, right) is generally an excitatory neurotransmitter that is present in 
both central and peripheral nervous system. It is known to be involved in movement control, 
sleep-wake cycle, cognitive processing.  
 
           
                     
 
Figure 7: Molecular structures of tyrosine (left) and dopamine (right), (Campbell and Reece, 2005). 
 
     Dopamine is catecholamine - that is, it is derived from amino acid tyrosine (Figure 7, left). 
Tyrosine is converted into 3,4-dihydroxyphenylalanine (DOPA also know as L-DOPA) by 
enzyme called tyrosine hydroxylase (TH) (Figure 8). DOPA (L-DOPA) is converted into 
intracellular dopamine by an enzyme dopadecarboxylase (DD) (Stewart A et al., 2002). 
Dopamine can be further converted to other neurotransmitters, like noradrenaline and 
adrenaline, but the enzymes that catalyze these reactions are not synthesized in dopaminergic 
neurons (Jensen, 2006). Inside the cell, dopamine is kept in vesicles, therefore it’s 
concentration in the cytoplasm is relatively low (Best et al, 2009). After release into the 
synaptic cleft, dopamine binds to receptors on postsynaptic membrane of receiving neuron. 
D1 and D2 receptors are the most relevant subtypes for understanding the way dopamine is 
involved in control of motor functions in the brain (see Basal ganglia).  
     While in the synaptic cleft, dopamine is also rapidly taken up by nearby glia cells and 
back through presynaptic membrane (reuptake) by dopamine transporters into neuron. These 
transporters are thought to be important in maintenance of extracellular concentration of 
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dopamine. Dopamine also binds to presynaptic receptors (see figure 8), which causes increase 
or inhibition in activity of tyrosine hydroxylase and therefore affects dopamine synthesis 
(presynaptic feedback regulation). For example it has been estimated that, increased 
concentration of extracellular dopamine can inhibit activity of tyrosine hydroxylase by at 
least 50 % (Best et al, 2009).  
     If not packed into vesicles, dopamine in the cytoplasm is broken down by monoamine 
oxidase into 3,4-dihydroxphenylacetic acid (DOPAC).  
 
 
 
Figure 8: Dopamine metabolism. TYR, tyrosine; DOPA, 3,4-dihydroxyphenylalanine; DA, dopamine; TH, tyrosine 
hydroxylase; DD, dopadecarboxylase; V, vesicles; REL. release; RUPT. reptake; PRE. REC. presynaptic receptor; PFR, 
presynaptic feedback regulation; DOPAC, 3,4-dihydroxphenylacetic acid; MAO, monoamine oxidase. (Stewart A et al., 
2002). 
 
 
 
 Historical background of Parkinson’s disease  
 
     Parkinson’s disease – the second most common neurodegenerative disorder was first 
described in 1817 by neurologist James Parkinson as ‘‘Shaking Palsy’’ or ‘‘paralysis 
agitans’’ disease, the symptoms of which include: involuntary tremulous motion, with 
lessened muscular power, in parts not in action and even when supported; with a propensity 
to bend the trunk forward, and to pass from walking to a running pace: the senses and 
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intellects being uninjured. In 1912, inclusion bodies (Lewy bodies) (see Causes of 
Parkinson’s disease) that are now considered to be a distinctive feature of Parkinson’s 
disease, were first described by Friedrich Heinrich Lewy. Later on in the 20th century, the 
loss of pigmented cells in the substantia nigra pars compacta was observed in patients with 
Parkinson’s disease. The link between the loss of dopamine producing neurons and 
Parkinson’s disease was made by A. Carlsson in 1950’s. He also discovered the fact that 80% 
of dopamine producing neurons are located in the basal ganglia. (Bartels and Leenders, 2009) 
 
 
 
 Causes of Parkinson’s disease  
 
     Parkinson’s disease is considered to be a sporadic disorder, which means that no clear 
connection between individual cases has been found. Several hypotheses have been proposed 
as to what causes Parkinson’s disease. Cases caused by known inherited genetic 
abnormalities account for less than 10% of the overall PD cases. (Lees et al, 2009) This 
means that heredity is either not the main causing factor or other unknown mutations are 
present.  
     Another possible cause of Parkinson’s disease is exposure to exogenous toxins. 
Exogenous toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been 
proven to cause parkinsonian syndrome (similar to Parkinson’s disease). This discovery and 
the fact that people who lived in an environment polluted with MPTP alike pesticides had a 
relatively high risk for developing Parkinson’s disease supports the idea of environmental 
origins of Parkinson’s disease (Bartels and Leenders, 2009). MPTP affects the chain of 
respiratory reactions in the inner mitochondrial membrane specifically in dopaminergic 
neurons, which eventually leads to energy depletion and death of a neuron. (Bartels and 
Leenders, 2009). In different research articles we used for our project MPTP and other 
neurotoxins like 6-hydroxydopamine (6-OHDA) were used in many laboratory experiments 
as means to selectively kill dopaminergic neurons and induce PD-alike condition in animal 
models to test stem cell therapy.  
1st Semester, Fall 2009: Juliette Tavenier, Evelina Martinenaite, Elayne Elvira Lorenzen & Ursula Izabel Waltemath 
24 
 
     Despite effect of MPTP on respiratory system in neurons, several hypotheses of cellular 
mechanisms of neurodegeneration in Parkinson’s disease were proposed (Bartels and 
Leenders, 2009):  
 Oxidation hypothesis – Deficient antioxidant system which results in free toxic oxygen 
radicals that may damage dopaminergic neurons. Metabolism of dopamine (see figure 8) 
(by monoamine-oxidase (MAO)) includes formation of peroxide as a waste product, 
which is normally decontaminated. In Parkinson’s disease accumulation of peroxide may 
cause irreversible damage inside dopaminergic neurons, which may result in cell death 
(Bartels, Leenders, 2009).  
 Decreased activity of proteasome – Normally proteasomes degrade misfolded or 
unneeded proteins inside the cell; therefore deficiency in this system results in 
accumulation of such proteins and thus may lead to disorders in normal functions of the 
cell. This hypothesis might explain formation of large protein aggregates, called Lewy 
bodies, inside dopaminergic neurons in Parkinson’s disease. However, it is unknown 
whether Lewy bodies are formed to clear misfolded/excess proteins from the cytoplasm 
(i.e. act as response to neurodegeneration) or cause neurodegeneration (Bartels, Leenders, 
2009).  
 Activation of glial cells (astrocytes and microglia) – Glial cells, such as astrocytes and 
microglia, might also intervene in the mechanism of degeneration (Bartels; Leenders, 
2009). Since astrocytes maintain appropriate chemical environment for neurons and 
microglia remove damaged cells (Purves D et al, 2001), any disorders in the function of 
these cells might fatally affect neurons.  
 
     These hypothetical changes in metabolism may be the result of both genetic and 
environmental influence and it is still unclear which is more important. Therefore, generally 
accepted theory states that Parkinson’s disease is the result of both environmental and genetic 
impact. 
 
 Imaging of Parkinson’s disease  
 
     One of the first non-invasive techniques used to diagnose PD and evaluate dopaminergic 
integrity of the parkinsonian brain is positron emission tomography (PET). Several different 
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biological markers can be used in this technique to monitor abnormal changes in the 
metabolism of specific brain regions: metabolism of levadopa (tracer 18F-dopa), presynaptic 
dopamine transporter – DAT (tracers 11C-CFT, 18F-CFT, 11C-RTI-32, 18F-FP-CIT, 11C-
methylphenidate), type-2 vesicular monoamine transporter – VMAT2 (tracer 11C-
dihydrotetrabenazine) (Pavese, Brooks; 2009).   
     Other techniques: single-photon emission computed tomography (SPECT), magnetic 
resonance imaging (MRI) and transcranial sonography (TCS). 
 
 
 
 Treatment of Parkinson’s disease: 
 
     Parkinson’s disease is characterized and diagnosed by the loss of dopamine producing 
(dopaminergic) neurons in substantia nigra (see figure 9).  
 
Figure 9- Substantia nigra in the normal brain and in brain of patients with Parkinson’s disease. (The New York Times 
Health. Parkinson's Disease Overview) 
      There are three different ways that can be used to treat Parkinson’s disease: drug 
(replacement) therapy, deep brain stimulation (DBS) and stem cells transplantation. One of 
the most common ways to treat the symptoms of Parkinson’s disease is the replacement 
therapy, which aims to restore the levels of dopamine in a specific brain region. Difficulties 
in such pharmaceutical treatment of Parkinson’s disease arise from the blood-brain barrier, 
which creates different environment in the brain compared to the blood plasma, and therefore 
it is selectively permeable to different molecules in the blood, including drugs. So, dopamine 
itself cannot be used since it would not pass the blood-brain barrier.  However, to achieve the 
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same result, the dopamine precursor L-DOPA is used. L-DOPA can pass through the blood-
brain barrier and is then transformed into dopamine within the cells (including dopamine 
neurons). The use of L-DOPA helps to achieve the principle goal of the treatment – the 
improvement of the motor symptoms in patients with Parkinson’s disease. Dopamine 
agonists can be added to the L-dopa and their advantage is that they can function without host 
dopamine neurons. An agonist is a drug that binds to a receptor of a cell and triggers a 
response by the cell. Unfortunately, only 1-5% of the L-DOPA enters the dopamine neurons 
and the rest is metabolized to dopamine elsewhere which then causes many side effects such 
as dyskinesia (involuntary movements) during the long term treatment.  
     The use of dopaminergic drugs or high-frequency stimulation of the GPi or STN (refer to 
figure 3) to treat PD is likely to reduce the synchronized oscillatory activity, and to suppress 
the excitation of the BG output nuclei GPi and SNr. However, the deep brain stimulation as a 
way of treating cognitive and psychiatric dysfunction in patients with PD proved to be 
inefficient. This treatment is broadly used but the patients still need to be maintained on L-
dopa. The cognitive or emotional symptoms may be aggravated by STN more than GPi 
stimulation (Voon et al., 2006).  
     Stem cell-based regenerative neurological therapy is a new revolutionary concept for 
treating Parkinson’s disease. Although the adult brain contains Neural Stem Cells (NSC), 
they are not powerful enough to promote full, stable and functional recovery of the central 
nervous system (CNS) when structural lesions occur. The CNS itself also has limited self-
repair capabilities (Jurga et al., 2009). Due to these limitations, stem cell-based therapies are 
relevant in becoming a plausible alternative in treating neurological disorders. Potential 
pathways for stem-cells delivery include: direct brain transplantation as well as intravenous 
or selective endovascular infusion. The survivals of transplanted cells, as well as their 
differentiation and proliferation properties are limited by the histocompatibility between the 
recipient and the donor. It has this partial limitation, but it is strongly dependent on local 
microenvironment upon transplantation. An alternative strategy is based on the 
transplantation of artificial tissue based on biodegradable scaffolds. These artificial neural 
tissues can be shaped to the lesion size according to the results of the magnetic resonance 
imaging (MRI) scanning and can be delivered directly into the cavity. Artificial tissue based 
on biodegradable supporting material should be more resistant to the usual stress of 
transplantation than dispersed stem cells (Jurga et al., 2009).  
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 Fetus’ development   
 
     Stem cell therapy as a treatment for Parkinson’s disease involves the use of stem cells 
taken from human embryos. Therefore it is relevant to understand the process of fetal 
development for perception of both scientific and ethical aspects in the development of 
treatment.  
     The term embryo refers to the developing human from the moment of the implantation 
until the eighth week of pregnancy. After the eighth week, the child is referred to as a 
fetus. In this part, we’re going to focus mostly on the fetus’ development from day 4 to 
week 9, which represents the relevant period of embryonic development for our project. 
 
 
• 2 -3 days after fertilization: An embryo at this stage consists of identical cells that 
are totipotent, which means that each cell, on its own, could give rise to an embryo. 
This would lead to the development of identical twins or quadruplets, for example. 
They are completely unspecialized and contain the capacity to differentiate into any of 
the cells that will make up the placenta and membrane around the fetus, as well as the 
fetus itself (McLaren et al., 2000), (Minnesota Department of Health, 2009) 
 
 
• 4-5 days after fertilization: This stage is called the morula stage. During this phase, 
the embryo continues to be made up of unspecialized embryonic cells. However, these 
cells no longer can give rise to an embryo on their own (McLaren et al., 2000). 
 
• 5-6 days after fertilization: In this stage, called the blastocyst stage, a hollow 
appears in the center of the morula  (the mass of cells resulting from the cleavage of 
the ovum before the formation of a blastula), and the cells making up the embryo 
begin to be differentiated into inner and outer cells (Minnesota Department of Health, 
2009) 
- The outer cells- These cells will make up the tissues around the fetus, including the 
placenta. 
- The inner cells- The inner cells which are about 20 to 30 cells, will give rise to the 
fetus and to some of the surrounding tissues. Pluripotent cells can be derived if the 
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inner cells are isolated and are grown in the presence of certain chemical substances 
(growth factors). It is from these cells that the embryonic stem cells for the therapy for 
Parkison’s disease are derived. 
 
• 8 days after fertilization: By the eighth day, the blastocyst has already attached to 
the wall of the uterus, where it will grow rapidly. 
 
• First trimester (2- 12 weeks): During this stage, the embryo grows from about 1/100 
of an inch long to 3 ½ inches from head to rump. By four weeks, the embryo has 
developed a head and a trunk, a blood vessel forms (which will develop later into the 
circulatory system and heart), blood begins to be pumped, and a ridge of tissue starts 
to form down the length of the embryo. At six weeks, the heart already has its four 
chambers, and fingers and toes start to form. With the development of the brain and 
nervous system, reflex activity starts and the formation of ears, jaws, eyes, stomach, 
lungs, liver and intestines begin. At eight weeks, the embryo is now officially a fetus 
and the beginnings of all main body parts are formed. The skeleton and muscles 
continue to develop and the nervous system becomes more responsive. Between the 
tenth and twelfth week, there is the start of small movements, the growth of nails on 
fingers and toes, the ability to swallow, almost full development of the kidneys, then, 
full body movement, and the development of genitals (McLaren et al., 2000).  
 
 
   4.2 Discoveries on human stem cells  
     The treatment for infertility progressed immensely in the late 70’s and this progress made 
possible the birth of the first child by in-vitro fertilization (McLaren and Hermerén, 2000). 
This treatment consists of the formation of human embryos in vitro which made the study of 
human embryogenesis possible, making us more aware of the characteristics and behaviors of 
the embryonic cells at an early stage. Culture and derivation of embryonic and fetal human 
stem cells had been performed since 1998 (McLaren and Hermerén, 2000). This is a process 
that had never been achieved with human cells. In the following years, after research was 
done on adult stem cells, the plasticity of the cells was revealed to be much higher than 
1st Semester, Fall 2009: Juliette Tavenier, Evelina Martinenaite, Elayne Elvira Lorenzen & Ursula Izabel Waltemath 
29 
 
expected. By isolating cells from the bone marrow of children or adults, scientists showed 
that these cells had the ability to become muscle or neural cells (McLaren and Hermerén, 
2000). Nevertheless, cells from bone marrow with such extreme malleability are very rare. 
These initial findings lead to the amazing discoveries of the potential of stem cell therapy. 
(McLaren and Hermerén, 2000) 
 
 
4.3 Stem cells 
     The idea of stem cell therapy is to differentiate these stem cells into cells with the right 
phenotype of dopaminergic neurons and to implant them into the damaged part of the brain. 
Most of the experiments for this therapy are done on animal models. 
 
 Definition and potential: 
     A stem cell is an unspecialized and self renewing cell, which means that it can 
differentiate into many specialized cell types, such as neurons, blood cells, muscles; and is 
able to replicate itself without differentiating indefinitely (see figure 10).  
 
Figure 10- A stem cell is an undifferentiated cell that can replicate, or differentiate into many types of specialized cells. 
(The National Academies, 2009) 
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     Stem cells can be organized in different categories depending on their potency. The 
potency is the potential of differentiation into different types of other cells. These cells can be 
(see figure 11):  
1. Totipotent (or omnipotent) stem cells, which means they can differentiate into any of 
the possible type of cell; they can even generate a new organism. These cells are cells 
from early embryo (between 1 and 3 days). 
2. Pluripotent stem cells can differentiate into nearly all possible cell types. The cells 
from the blastocyst are an example of pluripotent cell. In the stem cell therapy for 
Parkinson’s disease, it is the cells from the inner membrane of the blastocyst that are 
used; these stem cells are pluripotent and not totipotent because they cannot develop 
into an embryo on their own. If they were to be transferred to a uterus, they wouldn’t 
implant or develop into an embryo. 
3. Multipotent stem cells are able to differentiate into a limited number of related 
families of specialized cells. Umbilical cord cells and adult stem cells are multipotent. 
4. Oligopotent stem cells such as lymphoid or myeloid stem cells, have a low potential 
of differentiation into other types of cells, they can only differentiate into a few 
specialized types of cells.  
5. Unipotent cells can only generate their own type of cells. These cells are for example 
adult muscle cells. 
     However, the stem cells used for the therapy are only the pluripotent and multipotent 
types, which are the pluritpotent cells derived from the blastocyst, and the multipotent neural 
adult and embryonic stem cells. 
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Figure 11- Illustration of stem cell classification. Cells of the zygote are totipotent being able to form an embryo and the 
trophoblast of the placenta, but they are not capable of extended self-renewal. Embryonic stem cells (ESCs), derived from 
the inner cell mass of the blastocyst, are capable of self-renewal and are pluripotent being able to generate cells from all 
three germ layers. Somatic stem cells are pluripotent being able to make cell types found in the tissue where they reside, 
whereas progenitor cells have limited proliferation and differentiation potentials (Jensen, 2006). 
 
       
 Stem cell division:  
     There are three different ways of stem cell division: symmetric division, asymmetric 
division and differentiative division. Symmetric division is the division of a mother stem cell 
into two identical daughter stem cells. The asymmetric division consists in a mother stem cell 
dividing into one stem cell and a progenitor cell, which as mentionnned earlier has a limited 
potential of differentiation. Finally the outcome of the differentiative division is two identical 
progenitor cells. (see figure 12) 
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Figure 12- Illustration of neural stem cell division. Stem cells (S) can undergo: symmetric division giving rise to two 
identical daughter cells; or asymmetric division giving rise to one cell identical to the mother cell and one more ‘committed’ 
progenitor cell (P); or differentiative division giving rise to two progenitor cells. The progenitor cells are capable of limited 
self-renewal before differentiation into linagespecific progeny termed neuroblasts and glioblasts. These lineage-restricted 
cells can still replicate before they differentiate into mature neurons, astrocytes, and oligodendrocytes (Jensen 2006). 
 
 
 
 
 Sources of stem cells: 
There are five major sources of stem cells that can be considered as donor for the treatment of 
Parkinson’s disease (see figure 13):  
- Fetal tissue from the ventral mesencephalon (VM tissue);   
- Neural stem cells (NSCs) from embryonic/fetal or adult brain; 
- Embryonic stem cells (ESCs) obtained from the inner cell mass of the blastocyst; 
- ES-like induced pluripotent stem (iPS) cells; 
- Other stem cells, such as umbilical cord, placenta and bone marrow. 
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Figure 13-  Five types of cells are considered as possible donor sources of transplantation for PD: embryonic/fetal ventral 
mesencephalic cells, neural stem cells, embryonic stem cells, fibroblasts and other stem cells. After culture and 
differentiation of these cells into progenitors of dopaminergic neurons, they are ready to be transplanted into the damaged 
brain (Modified from Morizane et al. 2008). 
 
 
 Embryonic Mesencephalon tissue: 
 
     The fetal tissue from the ventral mesencephalon is derived from 6-9 week-old aborted 
human embryos (Lindvall and Björklund 2004). This tissue can be implanted directly into the 
patient’s brain, it doesn’t need to be differentiated; indeed, the ventral mesencephalon being 
the part of the brain that contains the substantia nigra, in which the dopamine is produced and 
that becomes the last differentiated is already composed of DA neurons. Experiments with 
ventral mesencephalon tissues have been mostly conduced on animals, but also on humans. 
There has been until now, only 400 patients treated with this type of stem cell (Morizane et 
al, 2007). Several of these patients have experienced spectacular improvements both in the 
speed of movement and in the reduction of the rigidity. These experiments also showed that 
the grafts are fully integrated into the patient’s brain. Besides, these grafted cells seem to 
have a high potential of differentiation into DA neurons and to be able to survive for quite 
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long periods without degradation in their functionality. And even though the risk of tumor 
formation is low with the VM tissue, a persistent graft-induced dyskinesia has been 
diagnosed in some of these patients (Morizane et al, 2007). There is also a problem of the 
ethical nature of these stem cells and their sustainability; indeed, the treatment of one patient 
requires the tissues from three to five embryos. 
 
 
 Neural stem cells: 
 
     The neural stem cells can be derived either from the adult brain (e.g., from the patient’s 
brain) or from the fetal brain, here again, from an aborted fetus. Experiments on neural stem 
cells have been done on animals in most of the cases for the study of their differentiation, 
proliferation and transplantation; however, the potential of differentiation of human stem 
cells has also been studied (Morizane et al, 2007). The advantage of the NSCs is that they 
have a very low risk of tumor formation (Morizane et al, 2007). However, these cells are only 
multipotent and have a low potential of differentiation into DA neuron and of proliferation 
inside the brain. Also, the growth of the NSCs from the adult brain is difficult. Studies in 
monkeys show the efficient capacity of neural stem cells (NSCs). Experiments on animals 
have shown that recognizing the potential use of NSCs leads to new opportunities in therapy 
(Burnstein et al, 2009). Therefore, there is a large need for a supply of human NSCs. Neural 
stem cells taken from the fetal and adult central nervous system (CNS) are well characterized 
but recently, stem cells from embryos have been used as a source of human tissue 
(Johannides, Chandran, 2007).   
 
 
 
 Human embryonic stem cells: 
 
     The human embryonic stem cells (hESCs) are derived from the inner mass of the 
blastocyst, which is composed of around 30 pluripotent cells; these cells have a high potential 
of differentiation, they can differentiate into any type of cell. An advantage of working with 
these cells is that they can be identified visually. Embryonic stem cells are round, small and 
form tight colonies (Whitehead Institute for Biomedical Research, 2007). The blastocyst 
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stage of the fetus is reached at around 4 to 5 days after fertilization (McLaren et al., 2000). 
Human embryonic stem cells, due to their proliferation potential and morphogenetic abilities, 
give a potentially unlimited supply of neural stem cells. Their high potential of proliferation 
makes them the most interesting source of donors for the stem cell therapy. Regardless of 
how precise the mechanism of action is, there is a requirement for the generation of sufficient 
amounts of derived cells for potential clinical use and characterization. Using existing 
protocols, there is an inability to generate sufficient numbers of human NSCs from fetal and 
adult-derived tissue. In contrast, human embryonic stem cells (hESCs) offer an unlimited 
supply of NSCs, thanks to their extremely high potential of proliferation in vitro; indeed, they 
can replicate indefinitely without differentiating (Joannides and Chandran, 2007). As 
mentioned, human ESCs are capable of undifferentiated proliferation and have the potential 
to generate all cell types. Studies on mice have shown that mouse embryonic stem cells have 
the capacity to be differentiated into NSCs (Johannides, Chandran, 2007). This ability, to 
program precursors, is distinctively a property of ESC-derived NSCs and therefore has an 
advantage over other neural stem cell systems where programming and directed 
differentiation has not been proven to be effective. However, in use of hESCs risk of tumor 
formation is present due to their genetic features in humans: in some experiments, karyotypic 
changes have been reported. It makes them proliferate extremely rapidly and shorten the time 
needed for the cells to duplicate. (Morizane et al, 2009).  
There is two ways of producing these ESCs:  
- In vitro fertilization: the in vitro fertilization starts by an ovarian stimulation of a 
women, which stimulates her ovaries so that an important number of follicles develop. 
Then the woman’s eggs are retrieved by a surgical procedure and fertilized by sperm in 
vitro. These eggs will divide and become blastocysts whose inner cells can be cultured, 
differentiated into DA neurons and then implanted in the damaged brain. 
- Somatic cell nuclear transfer: this process consists of inserting the nucleus of a patient’s 
already differentiated somatic cell, into an unfertilized egg that has its nucleus removed. 
The egg is then stimulated by an electric signal and divides in order to form a blastocyst. 
The blastocyst obtained contains the genetic material of the somatic cell, and can now be 
source of stem cells which after expansion and differentiation in any type of cell, since 
they are pluripotent, will be reimplanted in the patient (see figure 14). These stem cells 
have the genetic material of the patient, and therefore cannot be rejected after 
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implantation. However, there is a risk that neurodegeneration might reoccur since the 
cells also contain the genetic failures of the patient.  
 
 
 
Figure 14- 1) An unfertilized egg is taken from a woman, and the nucleus of this cell is extracted. Then, the nucleus of a 
somatic cell taken on the patient’s body is inserted into the enucleated egg cell. 2) The egg cell is stimulated divide and 
forms a blastocyst. 3) The obtained stem cell can now be expanded and differentiated into any type of cell before 
reimplantation into patient. (Stem Cell Research, 2009).  
 
 
 
 Embryonic Stem-like induced pluripotent stem cells:  
 
     Experiment on mice showed successful results concerning the differentiation of fibroblasts 
into dopamine neurons (Wernig et al. 2008). Fibroblasts are somatic cells synthesizing the 
extracellular matrix and collagen, they are found in the connective tissue (See figure 15). The 
connective tissue is the material made up of fibers found between the cells; it supports the 
structure of the body. Fibroblasts could be induced into stem cells by a cellular 
reprogramming. The advantage of this source of stem cells is that if the somatic cells are 
taken from the patient and then transplanted into his brain, the immune response is avoided 
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(Wernig et al. 2008). However, there is still a possibility of tumor formation and there is also 
a risk that the disease reappears because of the genetic failures that the DNA of the patient 
contains, since the cells used are the patient’s own cells. (Lindvall and Kokaia, 2009). 
Figure 15: Extracellular matrix: connective tissues and fibroblasts [Wikipedia 2009]. 
 
 
 
 
 Human umbilical cord blood stem cells: 
 
     In contrast to embryonic and induced pluripotent stem cells, transplantation of human 
umbilical cord blood-derived neural stem cells line (HUCB-NSC) into immunodeficient mice 
has never caused tumors (Jurga et al., 2009). In general, there is a lack of organ donors in the 
world (Jurga et al., 2009). Because of this, stem cell- based regenerative medicine is now 
exposed to a vast choice of sources of pluripotent stem cells, but their potential for clinical 
use needs to be better evaluated. The issues that arise when discussing clinical use are the 
safety and funcionality of the recruitment. When considering accessibility, low cost, safety, 
and broad differentiation potential, HUCB-NSC has become one of the most promising tools 
for stem cell-based regenerative therapy (Jurga et al., 2009). However, in order to make these 
procedures standardized, stem cells isolated from HUCB need to be elucidated to examine the 
prolonged proliferation of these cells and their differentiation toward functional neurons. 
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 4.4 Stem cell therapy for Parkinson's disease 
     The idea of using stem cells transplantation as a treatment for PD is to implant donor cells 
that contain the phenotype of the dopaminergic neurons of the substantia nigra pars compacta 
the phenotype is induced by the high proportion, in the graft, of cells called TH+ (TH 
immunoposotive) neurons after differentiation (Wijeyekoon and Barker, 2009). In order to be 
successful, the therapy should induce a dramatic and long-lasting improvement of the 
mobility; it must also have a high percentage of proliferation and differentiation of the stem 
cells into DA neurons. However, it should not be associated with dyskinesia or any other 
therapy-induced pathology, and neither should it have a risk of graft rejection and tumor 
formation. 
 
 
 Stem cells from the fetal ventral mesecephalon: 
 
     Stem cells derived from the ventral mesencephalon do not need to be differentiated; after 
dissection of the tissue, the cells can be used in three different formulations, single cells 
suspension, solid pieces and tissue strands depending on the clinical studies. (Hedlund and 
Perlmann 2009) The progenitors are expanded; their survival rate is increased and then 
injected into the brain of the patient.  
 
     An important issue with this therapy is the cellular composition of the graft. The 
embryonic ventral mesecephalic graft contains DA neurons with the right substantia nigra 
pars compacta phenotype. A regular foetal ventral mesencephalon contains around 5% of 
dopamine neurons; the remaining cells are in majority glial cells, and also serotoninergic, 
GABAergic. However, the proportion of these neurons depends on a lot of variables such as 
the age, the donor tissue dissection of the embryo, the method of dissection, the formulation 
of the graft. It has been shown that the proportions of each type of neurons in the grafts can 
lead to significant differences in the outcome of the experiments. For instance, in experiments 
on rats confirms that grafts containing a small proportion of dopamine neurons relative to 
serotonin neurons causes an aggravation of L-dopa induced dyskinesia (Hedlund and 
Perlmann, 2009). However, grafts containing a high level of dopamine result in amelioration 
in dyskinesia, independently of the proportion of serotonin. Also the level of dopamine still 
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present in the damaged brain is important regarding to the grafted serotonin neurons; they 
increase risks of worsening the L-dopa induced dyskinesia when the patient is at an advanced 
stage of the disease: when the proportion of dopamine in the striatum that is still effective is 
below 10-20%. Indeed, as mentioned earlier, a low percentage of DA neurons compared to 
serotonin neurons can worsen the L-dopa induced dyskinesia; if a patient who is at an 
advanced stage received a graft which contains a high proportion of serotonin, the dyskinesia 
will get worst. This means that even a really low amount of serotonin in a overly damaged 
brain can cause dyskinesia. Another stem cell therapy-induced pathology is the formation of 
Lewy bodies. Present in the affected brain, they have also been found in the grafted tissues 
after a certain amount of time (Hedlund and Perlmann 2009). They are abnormal 
aggregations rich in proteins such as ubiquitin and α-synuclein that develop inside the nerve 
cells. A mutation or over expression of α-synuclein can be the cause of familial PD; it has 
been show that a PD-like disease can be induced in animals by mutation or increased gene 
dosage of the protein. It is has been found that Lewy bodies reappear only in 10 year-old, or 
more, transplants of DA neurons, which means they need at least one decade to develop 
(Lindvall and Kokaia, 2009). However, it is unknown if these bodies are really harmful; 
indeed, some experiments suggest that they actually sequester toxic proteins: high number of 
these bodies was associated to a decrease in the toxicity of α-synuclein in models of PD. 
Hence scientists cannot conclude that the presence of Lewy bodies is related to a 
degeneration of the neurons. The transplanted cells also seem to undergo a decrease in the 
tyrosine hydroxylase (TH) immunoreactivity, which is also thought to be a protective 
mechanism (Hedlund and Perlmann, 2009).  
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 Embryonic stem cells, neural stem cells and induced pluripotent stem cells: 
 
 
 
Figure 16: The following protocols have been used to generate dopaminergic neurons.  
 (a) Embryonic stem cells grown as embryoid bodies and differentiated with various factors or expanded with mouse 
stromal cells and genetically modified to overexpress transcription factor Nurr1.  
(b) Progenitors of embryonic VM and expansion with trophic factors, and overexpression of the genesWnt5a or Pitx3 
and consecutive differentiation in embryonic VM co-culture.  
(c) Subventricular-zone-derived cells from adult brain after expansion as neurospheres with growth factors, 
overexpression of the gene Nurr1 and differentiation with neurotrophins or Mash1.  
(d) Bone marrow stem cells after Notch overexpression, neuronal induction with growth factors and differentiation with 
GDNF.  
(e) Fibroblast-derived iPS cells after culturing as embryonic stem cells.  
Abbreviations: BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; CNS, central nervous 
system; CNTF, ciliary neurotrophic factor; EGF, epidermal growth factor; ES, embryonic stem; FGF-8, fibroblast 
growth factor 8; GDNF, glial-cell-line-derived neurotrophic factor; NT-3, neurotrophin 3; PDGF, platelet-derived 
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growth factor; SHH, sonic hedgehog; SVZ, subventricular zone; VM, ventral mesencephalon (Lindvall and Kokaia. 
2009). 
 
 
 
 Embryonic stem cells differentiation: 
     Experiments on embryonic stem cells are done mainly with mice, rats or monkey and not 
with human stem cells for ethical reasons. 
The undifferentiated ESCs are isolated and expanded into a gelatine-coated culture dish with 
leukemia inhibitory factor (LIF) which affects the development of the cells, helping the 
differentiation, but keeping their pluripotency and potential of proliferation; this is the first 
stage of differentiation for all different ways of culturing ESCs (Lee et al, 2000). 
 
There are two most commonly used ways of generating dopaminergic neurons from the 
embryonic stem cells: 
• The first protocol (see figure 16) starts by culturing and expanding the undifferentiated 
cells in a culture plate in presence of leukemia inhibitory factor and an ES cell 
medium; producing embryoid bodies is the second stage, it will increase the number of 
TH-positive neurons; a defined medium is then chosen in order to obtain the right 
phenotype (stage 3). Then, at the stage 4 the proliferation of the cells is stimulated by a 
mitogen (chemical substance triggering the cell division): the basic fibroblast growth 
factor (bFGF), and their differentiation is induced by the sonic hedgehog (SHH) 
protein, the fibroblast growth factor 8 (FGF-8) and ascorbic acid; these components 
will also help rising the yield of TH-positive neurons, the number of DA and serotonin 
neurons. And finally, the cell’s differentiation is triggered by the removal of the 
growth factor (Stage 5). As mentioned before, TH is an important constituent of the 
future grafted cells; experiments show that TH is not present before the stage 4 of the 
differentiation but is stimulated with the introduction of bFGF. However, it still needs 
some time and specific conditions in order to finally acquire the desired phenotype. It 
is during the last stage (stage 5), that the differentiation of the ESCs is stimulated by 
removing the bFGF from the medium and stimulating the differentiation (Lee et al., 
2000).  
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• The second protocol (see figure 16) begins by the expansions of the ESCs in co-culture 
with stromal cells; they are connective tissue cells such as fibroblasts. These stromal 
cells are used as feeder cells; it means that they release the nutrients into the culture 
medium. The undifferentiated ESCs are then co-cultured with the orphan nuclear 
hormone receptor Nurr1. The overexpression of the Nurr1 gene aims to stimulate the 
production of TH (Kim et al. 2003; Kim et al. 2006), help the cell’s differentiation and 
inhibit the formation of astrocytes which are star-shaped glial cells. Then the 
manipulation is similar to the stage 4 of the first protocol, which consists in triggering 
the differentiation of the cells by adding to the medium SHH, FGF-8 and ascorbic acid. 
 
     Both of these protocols result in the differentiation of embryonic stem cells to 
dopaminergic neurons with the right phenotype. Mice embryonic stem cells show excellent 
results with 90% of TH-immunopositive cells obtained during the processes of differentiation 
and proliferation (Morizane et al. 2007). 
 
 
 Neural stem cells differentiation: 
     The protocols for inducing DA neurons from neural stem cells are analogous for 
embryonic and adult stem cells (see figure 16). It starts with the isolation of the stem cells in 
culture medium similar to the ones used for the embryonic stem cells. Then the cell’s 
proliferation is stimulated with the help of bFGF, FGF-8 and SHH, or an epidermal growth 
factor (EGF) and bFGF for the embryonic neural stem cells; the same growth factors (EGF 
and bFGF) are used for the adult NSCs in addition with the platelet-derived growth factor 
(PDGF). Then, the production of TH and differentiation into DA neurons are stimulated by 
the overexpression of the genes Wnt5a (Parish et al. 2008; Sanchez-Pernaute et al. 2008), or 
Pitx3 (Linvall, Kokaia, 2009). In the adult stem cells, the production of TH is triggered by the 
Nurr1 gene overexpression. Finally, in the embryonic cell cases, the cells are differentiated in 
a co-culture with embryonic ventral mesencephalon tissues. The adult cells’ differentiation is 
induced by neurotrophic factor such as BDNF, NT3 or the gene Mash1; neurotrophic factors 
are proteins that increase the survival, development and the function of neurons.  
The neural stem cells are difficult to grow and the percentage of TH immunopositive cells 
obtained is really low: from 4 to 10% (Morizane et al. 2007). Culture of rat embryonic neural 
stem cells gave rise to 20-25% TH immunopositive cell (Wijeyekoon and Barker, 2009). 
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 Fibroblast reprogramming: 
      The reprogramming of ES-like induced stem cells such as fibroblasts starts by a culture 
with the reprogramming factors Octamer-4 (Oct4), SRY (sex determining region Y)-box 2 
(Sox2), Kruppel-like factor 4 (Klf4) and Myc (see figure 16), these factors are called 
Yamanaka factors; we can find them in high levels on embryonic stem cells (Chen and Liu, 
2009). Oct4 and Sox2 are important for inducing pluripotency into somatic cells. The role of 
Flf4 is to control the renewal of stem cells, their proliferation as well as their differentiation.  
Myc’s role is to suppress the fibroblast specific genes and to induce their growth and 
division. With Myc known to be an oncogene, the evolution of the graft should be controlled. 
Once the fibroblasts are reprogrammed into stem cells, their differentiation protocol follows 
the same stages as the protocol for embryonic stem cells.  
 
 
 
 Transplantation: 
 
          The transplantation of the different types of stem cells is more commonly made 
directly into the putamen (see figure 3) by using a needle. The choice of the putamen as the 
site of the injections is explained by its important loss of DA neurons due to the disease; 
indeed it is the site of the brain where there is the most significant depletion in DA 
concentration (see figure 5), and the fact that this region is widely involved in the motor 
control. Transplantation of ventral mesencephalic tissues in the substantia nigra in mice was 
unsuccessful (Chen, Palmer, 2008), the same results were observed for a transplantation in 
the same area of a patient’s brain (Hedlund, Perlmann 2009). The placement of the 
transplants varies from patient to patient: the denervated areas are not at the same location for 
all patients, but this problem can be solved by the use of PET scan to determinate the areas 
where the loss of DA is the most important (Linvall, Björklund, 2004). For some patients 
having a really widespread loss of dopamine neurons, injections outside the putamen are 
necessary to ensure success of the therapy (Lindvall, Kokaia, 2009). In nearly all cases, the 
injections are bilateral, this means the differentiated neurons are implanted in both 
hemispheres of the brain; there can also be three injection for better coverage of the affected 
areas.  
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 Immune response: 
 
     The most effective source of stem cells is thought to be the human embryonic stem cells, 
due to the dramatical improvement they showed in experiments on animals (Wang et al, 
2007). However, these stem cells, as well as all the other sources of stem cells that are not 
derived from the patient itself will never supply an exact tissue match with the patient. This 
can lead to immune responses of the brain against the implantation of the grafts causing the 
death of the grafts, or its rejection. However, the use of some immunosuppressive drugs such 
as glucocorticoids, which inhibit the activity of the immune system, can help solving this 
issue (Wang et al. 2007). The cyclosporine is also an immunosuppressive drug aiming to 
block the T-cells activity; and therefore, lower the risk of rejection of the transplant. Indeed, 
in experiments on monkeys researchers used an immunosuppressant which was injected from 
3 days before the transplantation. The injections are continued after implantation with a lower 
dose until the end of the experiments (Muramatsu et al, 2009). 
 
 
 
 Risk of tumor formation:  
 
     Tumors are often the result of the proliferation of undifferentiated cells contained in the 
grafts; therefore, it is really important that all cells differentiate before transplantation (Chen 
and Palmer, 2008).  
     Although the NSCs have a low risk of tumor formation, some studies have established the 
possibility that it happens (Morizane et al., 2007); NSCs have been proven to be similar to 
glioma stem cells (glioma is a type of tumor caused by glial cells), and if there is 
undifferentiated cells in the graft, there is a possibility that these cells form a tumor.  
         As mentioned earlier, the ESCs are known to be unstable this, added to the already fast 
rate of proliferation of this type of cells could induce the formation of tumors (Morizane et al, 
2007). In studies of transplantation of ESCs in mice, 44% of the animals have developed 
tumors (Wang et al., 2007). 
         Since iPS are differentiated in co-culture with embryonic stem cells and these cells 
present a high risk of tumor formation, there are also high chances of cancer development 
with the use of iPS (Linvall and Kokaia, 2009). In the experiments conducted by Werning et 
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al. (2008), 16 out of 36 iPS transplanted mice died only a few months after injection, most of 
them had developed tumors. In other experiments (Chen and Liu, 2009), 20% of the mice 
developed tumor due to the presence of the oncogene Myc. 
 
 
 
 
   4.5 Ethical aspect: 
 
     There are two principles that we tend to place on a scale of high importance. First is the 
belief that we should do everything in our power to prevent or alleviate suffering, and second, 
simply the respect and value for human life. Stem cell research, in general satisfies the first 
principle in that it exists for the potential benefit of those who are suffering, in hopes of 
providing cure or at very least, relieving the suffering. Embryonic stem cell research, on the 
other hand, results in conflicts which are yet to be solved. The harvesting of embryonic stem 
cells is known to have a considerable potential to bring about astonishing benefits in serious 
medical conditions (Department of the Parliamentary Library, 2002). Therefore, it follows the 
first principle. Although the first principle is satisfied, harvesting human embryonic stem 
cells violates the second principle because the result is the destruction of human life. Due to 
these principles, the possibility and existence of destructive embryo research is considered to 
have moral problems and apparently, does not have the possibility to respect both principles 
simultaneously. The question is which principle should be considered of higher importance in 
this situation? Should we value the first principle and allow destructive stem cell research? Or 
should we give more value to the second and prohibit destructive embryonic research due to 
the fact that it violates the respect for a potential human life? This is a sensitive topic in 
which opinions vary even within our group. It is a matter of personal judgment and priority 
since it is not possible to satisfy both principles.  
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5.  Discussion 
      
     The causes of Parkinson’s disease are still unknown. If Parkinson’s disease was only the 
result of genetic disorders, stem cell therapy would be the only treatment providing suitable 
result – relief of the symptoms and possibly inhibition of further progression of the disease. 
However, only very few cases of PD can be defined as the result of inherited genetic disorder 
(Lees et al., 2009).  
     Since environmental factors inducing PD are unknown, the treatment using stem cell 
therapy might only be part of the solution to the problem of worldwide increasing cases of 
PD. Exposure to certain environmental factors might cause DNA damages in the neurons and 
therefore cause changes that cannot be treated using dopamine replacement technique or deep 
brain stimulation. In this case stem cell therapy is also the only possible way of treatment. 
However even after successful replacement of damaged neurons by healthy dopamine 
producing neurons derived from stem cells, PD can be induced again by the same external 
factors and therefore the long-term efficiency of stem cell therapy would be reduced. Another 
possible drawback of the use of stem cell therapy might appear if further research in the 
mechanisms of early progression of PD would show that damage of dopaminergic neurons is 
not the main cause of symptoms and that degeneration of other neuronal systems might be 
involved. 
     Based on the presented knowledge, the idea of stem cells therapy to treat Parkinson’s 
disease still seems like a promising and perspective research field. Establishment of a new 
therapy would start by generating dopaminergic neurons from stem cells. Based on the 
researches of different types of stem cells to treat PD, it can be concluded that none of the 
stem cells can fulfill all the criteria to be the perfect cure for PD. In a perfect case, stem cells 
used to create healthy neurons for the treatment should have high potential of proliferation 
and differentiation, be easily accessible, have a high survival rate and low probability of 
tumor formation and do not induce immune response. VM tissues are a good source, because 
of their high differentiation potential, post-grafted survival and the absence of tumor 
formation risk; however, ethical problems and donor supply cannot be neglected 
disadvantages. NSCs have a low chance of tumor formation, but are difficult to cultivate and 
differentiate. On the other hand, ESCs are easy to differentiate and have a high potential of 
proliferation, but their high potential of differentiation and rapid proliferation makes their 
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growth difficult to control and therefore there is a risk of tumor formation. iPS act similarly 
to ESCs, but their main advantage over ESCs is that they cannot be rejected by the host 
organism, since they contain the same genes.  
     As a conclusion, we can propose that among all the different types of stem cells, iPS seem 
to be the most promising ones in the treatment of PD. However, several questions still remain 
and further researches need to be carried out. 
 
 
 
 
6.  Perspectives 
       
     Just like stem cells therapy, other innovative therapeutic treatments are being explored and 
assessed by researchers for treating neurodegenerative diseases (NDs). The application of 
nanotechnology as therapy for Parkinson’s disease is expected to engender physiological 
responses by stimulating, responding to and interacting with target sites (Modi et al., 2009). 
Unlike common drug delivery systems, this novel therapeutic modality is predicted to 
provide the adequate features necessary for functional recovery in NDs such as PD (e.g. cyto-
architecture restoration, connection patterns). 
     One of the nanotechnological applications used to treat PD is the nano-enabled gene 
delivery. This technique represents a relatively new gene therapy and it consists of 
condensing DNA plasmids into nanoparticles and then delivering them to the brain. (Modi et 
al., 2009). The use of nano-enabled gene delivery represents a powerful strategy to overcome 
the different problems associated with drug delivery across the blood brain barrier (BBB) and 
the possibility of using it to stop or prevent the neurodegenerative process is still being 
assessed by researchers. 
     Another nanomaterial called nanorobots, is considered as a nascent science capable of 
treating PD. In the case of a patient suffering from this neurodegenerative disease, full 
regression of motor deficit would be possible if the original connections with neurons are 
repaired. Unfortunately, in adult brain, axon growth occurs in the wrong direction because of 
unfavorable conditions (Modi et al., 2009). To overcome this problem, researchers are 
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assessing the feasibility of nanorobots to transport and guide cells. Indeed, nanorobots are 
expected to ensure axon growth in the correct direction by stimulating and controlling the 
growth of neurons along the surface of dysfunctional neurons, in the zone of progressive 
degeneration (Modi et al., 2009). 
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APPENDIX: 
 
• Arborise- branch out like trees 
• Ascorbic acid- vitamin C                  
(http://www.medterms.com/script/main/art.asp?articlekey=12536) 
• Astroglia- characteristic star-shaped glial cells in the brain and spinal cord 
(Wikipedia) 
• Basal ganglia- a group of nuclei in the brains of vertebrates, situated at the base 
of the forebrain and strongly connected with the cerebral cortex, thalamus and 
other areas. (Wikipedia) 
• Biodegradable- Capable of decaying into the environment through natural 
processes consisting of living organisms. 
• Brain parenchyma- The specific tissues of the brain 
• Catecholamine– compound synthesized from amino acid tyrosine  
• CD113- Cluster of Differentiation 113 
• Dopaminergic- relating to, or activated by dopamine or related substances. 
(Dictionary.com) 
• Elucidate- To thrown light upon; highlight; make clear. 
• endoplasmic reticulum- 
• Fibroblast growth factor 8- Involved in the embryonic development and cell 
growth 
• Glucocorticoids- Steroids hormones that helps turning the immune activity down 
• Golgi apparatus- An organelle found in most eukaryotic cells (Wikipedia) 
• Grafting- Surgery 
• Growth factors- Substance helping the cellular growth, proliferation and 
differentiation 
• Histocompatibility- Having antigenic similarities so that cells or tissues 
transplanted from a donor to a recipient, are not rejected. 
• Human embryogenesis- Process of cell division and cellular differentiation of the 
human embryo during early prenatal development (from the moment of 
fertilization to the end of the 8th week of gestational age) 
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• Interneurons- Any neuron having its cell body, axon, and dendrites entirely 
within the central nervous system, especially one that conveys impulses between a 
motor neuron and a sensory neuron. 
• Intravenous- Within a vein 
• L-DOPA- L-3,4-dihydroxyphenylalanine 
• Lesions- Injury or wound 
• LIF- Leukemia inhibitor factor 
• Lysosomes- a cell organelle containing enzymes that digest particles and that 
disintegrate the cell after its death. (Dictionary.com) 
• Mitogen: A chemical substance that encourages a cell to commence cell division, 
triggering mitosis. (Wikipedia) 
• Morphogenetic- Having the ability the develop structural features of an organism 
• Neuroblasts- Immature nerve cells 
• Neurodegenerative disorders- Condition in which cells of the brain and spinal 
cord are lost. (Wikipedia) 
• Neurotrophic factors-  a family of proteins that induce the survival, development 
and function of neurons 
• Nuclear receptor related 1 protein- The orphan nuclear hormone receptor which 
is required for maturation of DA neuron precursors. (reference see Pitx3) 
• Pituitary homebox 3- A protein which is essential for the development of 
neurons specific to the SN; required for the development of the substantia nigra 
dopaminergic neurons. 
• Pluripotent- Having developmental plasticity 
• Proliferation- ”The growth or production of cells by multiplication of parts” 
(definition from dictionary.com)  
• Scaffold- A raised framework 
• Sonic hedgehog protein- Plays a key role in controlling the organization, shape 
and size of the brain. It controls cell division of adult stem cells. (Wikipedia..) 
• Substantia nigra- A deeply pigmented area of the midbrain containing 
dopamine-producing nerve cells 
• Trophic: That promotes cellular growth, differentiation, and survival 
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• Tyrosine hydroxylase- An enzyme that is required for the synthesis of L-tyrosine 
to L-dopa. (Wikipedia) 
• Unmyelinated- pertaining to nerve fibers that are not covered with a myelin 
sheath (Dictionary.com) 
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ABBREVIATIONS: 
 
• BDNF- Brain-derived neurotrophic factor 
• bFGF or FGF-2-basic fibroblast growth factor 
• CNS- Central nervous system; brain and spinal cords 
• CNTF- Ciliary neurotrophic factor 
• DA- Dopamine 
• DBS- Deep brain stimulation 
• ECM- Extracellular matrix 
• EGF- Epidermal growth factor 
• ES- Embryonic stem 
• FGF-8- fibroblast growth factor 8 
• GDNF- Glial-cell-line-derived neurotrophic factor 
• GPi- globus pallidus pars interna 
• hESCs or ESCs- (Human) embryonic stem cells 
• HUCB-NSC- Human umbilical cord blood-derived neural stem cells 
• iPS- Induced pluripotent stem  
• Klf4- Kruppel-like factor 4 
• L-DOPA- L-dihydroxyphenylalanine 
• LIF- Leukemia inhibitory factor  
• MAO- monoamine-oxidase 
• MPTP- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
• MRI- Magnetic resonance imaging 
• NSCs- Neural stem cells 
• NT-3- Neurotrophin 3 
• Nurr1- Nuclear receptor related 1 protein 
• Oct4-  Octamer-4 
• PD- Parkinson’s disease 
• PDGF- platelet-derived growth factor 
• Pitx 3- pituitary homebox 3 
1st Semester, Fall 2009: Juliette Tavenier, Evelina Martinenaite, Elayne Elvira Lorenzen & Ursula Izabel Waltemath 
58 
 
• PNS- Peripheral nervous system; sensory and motor neurons that connect to CNS 
• PPNc- Pedunculopontine nucleus pars compacta 
• SC- Stem cells 
• SHH- sonic hedgehog protein 
• SNpc- Substantia nigra pars compacta 
• SNr- substantia nigra reticulate 
• Sox2- SRY (sex determining region Y)-box 2 
• STN- Subthalamic nucleus 
• SVZ- subventricular zone 
• TH- tyrosine hydroxylase 
• TH+- tyrosine hydroxylase immunopositive 
• UPS- ubiquitin-proteasome system 
• VM- Ventral mesencephalon 
• VTA- Ventral tegmental area 
